Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19115699 | 0.80 | MAPT (0.35) | KDM4ERAB9A | |
| SCHEMBL19750612 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL11922167 | 0.76 | RAB9A (0.34) | ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL25910068 | 0.74 | KDM4E (0.30) | KDM4ERAB9A | |
| SCHEMBL20418258 | 0.74 | CYP19A1 (0.35) | ALDH1A1KDM4ENPC1RAB9AKIF11 | |
| SCHEMBL21287844 | 0.74 | KIF11 (0.32) | ALDH1A1KIF11 | |
| SCHEMBL18909931 | 0.71 | CYP19A1 (0.36) | ALDH1A1KIF11 | |
| SCHEMBL19602560 | 0.71 | — | — | |
| SCHEMBL23771970 | 0.69 | KIF11 (0.36) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL830406 | 0.69 | LMNA (0.30) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | ALDH1A1 1901/4885KDM4E 1425/4885NPC1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.